Frans Gustaf Wuite
Director/Board Member bei HERANTIS PHARMA OYJ
Profil
Frans Gustaf Wuite founded Araim Pharmaceuticals, Inc., where he worked as Chief Operating Officer.
Dr. Wuite also currently works at Herantis Pharma Oyj, as Vice Chairman from 2022, HealthCap VII GP SA, as Director, and Nukute Oy, as Director.
Dr. Wuite also formerly worked at Targovax Oy, as President & Chief Executive Officer from 2012 to 2015, Acesion Pharma ApS, as Chief Executive Officer from 2016 to 2020, BioCis Pharma Oy, as Director, Faron Pharmaceuticals Oy, as Director, Kompassi Gmbh, as Director, Amgen, Inc., as Principal from 1997 to 2009, N.V.
Organon, as Principal, Akzo Nobel, Inc., as Principal, Warren Pharmaceuticals, Inc., as Chief Operating Officer from 2005 to 2010, Van Leeuwen Buizen Groep BV, as Secretary & Legal Counsel, and Pharmacia-Leiras BV, as President.
Dr. Wuite received his Masters Business Admin degree in 1992 from the University of Tilburg and doctorate degree in 1986 from the University of Groningen.
Aktive Positionen von Frans Gustaf Wuite
| Unternehmen | Position | Beginn |
|---|---|---|
| HERANTIS PHARMA OYJ | Director/Board Member | 01.01.2014 |
| HealthCap VII GP SA | Director/Board Member | - |
Nukute Oy
 Nukute Oy Medical SpecialtiesHealth Technology Nukute Oy is a Finnish company that aims to improve the diagnosis of sleep apnea. Nukute is based in Oulu, FI. The company provides a Collare system that has been evaluated for its usability and clinical performance. The company was founded by Tuukka Visuri and Toni Leinonen, with Toni Leinonen serving as the CEO since incorporation. | Director/Board Member | - |
Ehemalige bekannte Positionen von Frans Gustaf Wuite
| Unternehmen | Position | Ende |
|---|---|---|
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Chief Executive Officer | 01.01.2020 |
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Chief Executive Officer | 01.11.2015 |
BioCis Pharma Oy
 BioCis Pharma Oy Pharmaceuticals: MajorHealth Technology BioCis Pharma is a clinical stage drug development company with the business idea to design and develop novel pharmaceutical products based on its proprietary technology platform. BioCis Pharma is targeting unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The first products are being developed for major medical indications in dermatology, ophthalmology, and urology. BioCis Pharma was founded in 2003 by Dr. Lasse Leino and Dr. Jarmo Laihia, two experienced research and development professionals with both industrial and scientific backgrounds. Since the start of its operation in December 2004, BioCis Pharma has shown exceptional ability to move product candidates forward in development programs, having now two high-potential products under clinical Phase I-II development. | Director/Board Member | 01.05.2014 |
Warren Pharmaceuticals, Inc.
 Warren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Warren Pharmaceuticals, Inc. develops tissue-protective technologies. The company was founded by Anthony Cerami and Michael Brines on May 17, 2001 and is headquartered in Tarrytown, NY. | Chief Operating Officer | 01.10.2010 |
| AMGEN INC. | Corporate Officer/Principal | 18.08.2009 |
Ausbildung von Frans Gustaf Wuite
| University of Tilburg | Masters Business Admin |
| University of Groningen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| FARON PHARMACEUTICALS OY | Health Technology |
| HERANTIS PHARMA OYJ | Health Technology |
| Private Unternehmen | 12 |
|---|---|
Organon NV
 Organon NV Pharmaceuticals: MajorHealth Technology N.V. Organon engages in the development, manufacture, and sale of prescription medicines. It offers products for cardiovascular diseases, fertility, gynecology, anesthesia, respiratory, consumer health care, neuroscience as well as immunology, animal health, and oncology. Its products include mometasone furoate inhalation powder, moxifloxacin, pegylated liposomal doxorubicin HCI, desogestrel, desloratadine, sun care, flu medicine, foot care, follitropin beta, formoterol fumarate inhalation powder, hormone therapy, and canine vaccines. The company was founded in 1923 and is headquartered in Oss, the Netherlands. | Health Technology |
Akzo Nobel, Inc.
 Akzo Nobel, Inc. Industrial SpecialtiesProcess Industries Akzo Nobel, Inc. provides decorative paints, performance coatings and specialty chemicals. Its products include catalysts, polymers, surfactants, and functional, pulp and paper chemicals. The firm's brands include Dulux, Sikkens and Eka. The company was founded in 1982 and is headquartered in Chicago, IL. | Process Industries |
BioCis Pharma Oy
BioCis Pharma Oy Pharmaceuticals: MajorHealth Technology BioCis Pharma is a clinical stage drug development company with the business idea to design and develop novel pharmaceutical products based on its proprietary technology platform. BioCis Pharma is targeting unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The first products are being developed for major medical indications in dermatology, ophthalmology, and urology. BioCis Pharma was founded in 2003 by Dr. Lasse Leino and Dr. Jarmo Laihia, two experienced research and development professionals with both industrial and scientific backgrounds. Since the start of its operation in December 2004, BioCis Pharma has shown exceptional ability to move product candidates forward in development programs, having now two high-potential products under clinical Phase I-II development. | Health Technology |
Warren Pharmaceuticals, Inc.
Warren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Warren Pharmaceuticals, Inc. develops tissue-protective technologies. The company was founded by Anthony Cerami and Michael Brines on May 17, 2001 and is headquartered in Tarrytown, NY. | Health Technology |
Van Leeuwen Buizen Groep BV
 Van Leeuwen Buizen Groep BV Industrial MachineryProducer Manufacturing Van Leeuwen Buizen Groep BV engages in the manufacture and distribution of steel pipes, and pipe and tube applications. Its product portfolio includes round tubes, valves, hollow sections, breams, pipe components, and bar steel. The firm also offers services including material treatments, digital services, testing and inspection, technical information, logistical services, and project management. The company was founded by Piet Van Leeuwen in 1924 and is headquartered in Zwijndrecht, the Netherlands. | Producer Manufacturing |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Health Technology |
| Pharmacia-Leiras BV | |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Araim Pharmaceuticals, Inc.
 Araim Pharmaceuticals, Inc. BiotechnologyHealth Technology Araim Pharmaceuticals, Inc. operates as a biotechnology company that develops novel treatments for devastating injuries and chronic diseases. It provides ARA 290, a novel 11 amino acid peptide that activates the body’s natural repair system through the innate repair receptor, which is present only following injury, as well as activates anti-inflammatory, tissue protective, and reparative signaling pathways. The company was founded by Anthony Cerami and Michael Brines in 2006 and is headquartered in Tarrytown, NY. | Health Technology |
| HealthCap VII GP SA | |
Nukute Oy
Nukute Oy Medical SpecialtiesHealth Technology Nukute Oy is a Finnish company that aims to improve the diagnosis of sleep apnea. Nukute is based in Oulu, FI. The company provides a Collare system that has been evaluated for its usability and clinical performance. The company was founded by Tuukka Visuri and Toni Leinonen, with Toni Leinonen serving as the CEO since incorporation. | Health Technology |
| Kompassi Gmbh |
